These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 9562524)

  • 21. A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
    Hou Y; McInnes B; Hinek A; Karpati G; Mahuran D
    J Biol Chem; 1998 Aug; 273(33):21386-92. PubMed ID: 9694901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel gene editing system to treat both Tay-Sachs and Sandhoff diseases.
    Ou L; Przybilla MJ; Tăbăran AF; Overn P; O'Sullivan MG; Jiang X; Sidhu R; Kell PJ; Ory DS; Whitley CB
    Gene Ther; 2020 May; 27(5):226-236. PubMed ID: 31896760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetics and Therapies for GM2 Gangliosidosis.
    Cachon-Gonzalez MB; Zaccariotto E; Cox TM
    Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 ganglioside.
    Sinici I; Yonekawa S; Tkachyova I; Gray SJ; Samulski RJ; Wakarchuk W; Mark BL; Mahuran DJ
    PLoS One; 2013; 8(3):e57908. PubMed ID: 23483939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ganglioside loading of cultured fibroblasts: a provocative method for the diagnosis of the GM2 gangliosidoses.
    Charrow J; Binns HJ
    Clin Chim Acta; 1986 Apr; 156(1):41-9. PubMed ID: 2938852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigating Immune Responses to the scAAV9-
    Kot S; Karumuthil-Melethil S; Woodley E; Zaric V; Thompson P; Chen Z; Lykken E; Keimel JG; Kaemmerer WF; Gray SJ; Walia JS
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
    Harzer K
    Clin Chim Acta; 1983 Nov; 135(1):89-93. PubMed ID: 6228344
    [No Abstract]   [Full Text] [Related]  

  • 28. The clinical aspects of adult hexosaminidase deficiencies.
    Federico A; Palmeri S; Malandrini A; Fabrizi G; Mondelli M; Guazzi GC
    Dev Neurosci; 1991; 13(4-5):280-7. PubMed ID: 1840098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosphingolipid degradation and animal models of GM2-gangliosidoses.
    Kolter T; Sandhoff K
    J Inherit Metab Dis; 1998 Aug; 21(5):548-63. PubMed ID: 9728335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis.
    Sango K; McDonald MP; Crawley JN; Mack ML; Tifft CJ; Skop E; Starr CM; Hoffmann A; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1996 Nov; 14(3):348-52. PubMed ID: 8896570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Presence of beta-hexosaminidase A alpha-chain mRNA in two different variants of GM2-gangliosidosis.
    Budde-Steffen C; Steffen M; Siegel DA; Suzuki K
    Neuropediatrics; 1988 May; 19(2):59-61. PubMed ID: 2967444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR/nCas9-Based Genome Editing on GM2 Gangliosidoses Fibroblasts via Non-Viral Vectors.
    Leal AF; Cifuentes J; Quezada V; Benincore-Flórez E; Cruz JC; Reyes LH; Espejo-Mojica AJ; Alméciga-Díaz CJ
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Promoters for the human beta-hexosaminidase genes, HEXA and HEXB.
    Norflus F; Yamanaka S; Proia RL
    DNA Cell Biol; 1996 Feb; 15(2):89-97. PubMed ID: 8634145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting the hexosaminidase genes: mouse models of the GM2 gangliosidoses.
    Proia RL
    Adv Genet; 2001; 44():225-31. PubMed ID: 11596985
    [No Abstract]   [Full Text] [Related]  

  • 35. Plasma G
    Blondel A; Kraoua I; Marcelino C; Khrouf W; Schlemmer D; Ganne B; Caillaud C; Fernández-Eulate G; Turki IBY; Dauriat B; Bonnefont-Rousselot D; Nadjar Y; Lamari F
    Mol Genet Metab; 2023 Feb; 138(2):106983. PubMed ID: 36709536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The GM2 gangliosidoses databases: allelic variation at the HEXA, HEXB, and GM2A gene loci.
    Cordeiro P; Hechtman P; Kaplan F
    Genet Med; 2000; 2(6):319-27. PubMed ID: 11339652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.
    Raghavan SS; Krusell A; Krusell J; Lyerla TA; Kolodny EH
    Am J Hum Genet; 1985 Nov; 37(6):1071-82. PubMed ID: 2934978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bicistronic lentiviral vector corrects beta-hexosaminidase deficiency in transduced and cross-corrected human Sandhoff fibroblasts.
    Arfi A; Bourgoin C; Basso L; Emiliani C; Tancini B; Chigorno V; Li YT; Orlacchio A; Poenaru L; Sonnino S; Caillaud C
    Neurobiol Dis; 2005 Nov; 20(2):583-93. PubMed ID: 15953731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular and clinical heterogeneity of adult GM2 gangliosidosis.
    Navon R
    Dev Neurosci; 1991; 13(4-5):295-8. PubMed ID: 1840100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.